Francis Medical Announces Close of Record $80 Million Series C Equity Financing
Summary
"Were extremely proud to be joining this funding round and investing in Francis Medicals development of a groundbreaking, disruptive therapeutic solution to treat prostate cancer," said David Strong, president and CEO of Orlando Health. Previously, the company was awarded FDA Breakthrough Device status for Vanquish on the strength of its VAPOR 1 Early Feasibility Study, published in the Journal of Endocrinology in November 2022. "This milestone is an important step forward in the fight to vanquish prostate cancer," said Michael Kujak, president and CEO of Francis Medical. "We are excited to be bringing this therapy to the U.S. market in late 2025 and are incredibly grateful to our investor partners for their dedication to making a meaningful difference in the lives of prostate cancer patients and are more confident than ever that this groundbreaking technology will ultimately become the first-line treatment of choice for men and their doctors. For more information on Francis Medical, visit www.francismedical.com or call (763) 951-0370.Vanquish Water Vapor Ablation System is currently an investigational device for treating prostate cancer.